Comparison of serum and bronchoalveolar lavage fluid sialic acid levels between malignant and benign lung diseases

Işıtmangil, Turgut; Işıtmangil, Gülbu; Budak, Yasemin; Aydilek, Recep; Celenk, Mehmet Kutlu

doi:10.1186/1471-2466-1-4

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В литературе имеются противоречивые данные, согласно которым содержание сиаловых кислот в крови больных раком легкого значимо превышает аналогичные показатели у здоровых доноров, а также у пациентов с неопухолевыми заболеваниями легких [19]. Однако значимых отличий уровня сиаловых кислот в крови и жидкости бронхиального лаважа у пациентов с раком легкого и неопухоле-выми заболеваниями не найдено [20]. Увеличение уровня сиаловых кислот в крови при раке легкого положительно коррелирует с метастазированием данной опухоли [21].…”

Section: Discussionunclassified

The level of sialic acids and imidazole compounds in the saliva of patients with lung cancer of different histological types

Бельская

Kosenok

2019

Sib. onkol. ž.

View full text Add to dashboard Cite

In recent years, the possibility of using known and new tumor markers in primary and differential diagnosis of lung cancer has been actively studied.The purpose of the studywas to study the level of sialic acids, the total content of imidazole compounds and seromucoids in the saliva of patients with lung cancer, depending on the histological type of tumor.Material and Methods. Total of 478 people took part in in the case-control study. They were divided into 3 groups: the main group (lung cancer, n=218), the comparison group (nonmalignant lung pathologies, n=60) and the control group (conditionally healthy, n=200).Results.Patients with non-malignant lung pathologies exhibited increased levels of imidazole compounds and seromucoids and decreased levels of sialic acids. A statistically significant decrease in the level of sialic acids was observed in patients with non-small cell lung cancer. The concentration of imidazole compounds was significantly higher in all study groups, except for carcinoid tumors. The nature of the changes in the studied parameters were ambiguous and depended on both the histological type of the tumor and the stage of the disease, including the presence / absence of distant and regional metastasis.

show abstract

Section: Discussionunclassified

The level of sialic acids and imidazole compounds in the saliva of patients with lung cancer of different histological types

Бельская

Kosenok

2019

Sib. onkol. ž.

View full text Add to dashboard Cite

show abstract

“…On the contrary, Isitmangil et al (2001) reported that sialic acid levels in bronchoalveolar lavage fluid and serum did not show any statistically significant difference between subjects with malignant and the non-malignant lung diseases (p > 0.05). Sialic acid levels were also unrelated to the stage and localization of the tumor (p > 0.05).…”

Section: Discussionmentioning

confidence: 87%

Sialic Acid Value in Pleural Effusion as a Diagnostic Marker of Malignancy

Alsayed¹,

Marzouk²

2014

Chest

View full text Add to dashboard Cite

“…In the current study, the main purpose of using combined measurement of tumor markers is to eliminate the false negative and false positive results as reported by many authors 10,18 . After reviewing our results as well as those of others, the question on the usefulness of combining markers in assessing early diagnosis of malignant liver disease is raised.…”

Section: Figure 1: Multiple Roc Curves For Afp Pivka-ii Vegf Sialimentioning

confidence: 98%

Diagnostic and Predictive Value of Some Tumor Markers in the Diagnosis and Follow Up of Patients with Hepatocellular Carcinoma

Abdel-Aleem

Wagih

Abou-Saif

et al. 2009

BESPS

View full text Add to dashboard Cite

Early detection of hepatocellular carcinoma (HCC) is essential for successful treatment. Although the role of alpha fetoprotein (AFP) in the diagnosis of advanced HCC is well recognized, at least one third of small HCCs and 15-20% of advanced HCC will be missed unless another diagnostic tool is used. Thus, new serologic markers with sufficient sensitivity and specificity are required. In the present study, we aimed at evaluating the diagnostic and prognostic role of AFP, protein induced by vitamin K absence or antagonist(P1VKA-II), vascular endothelial growth factor (VEGF), sialic acid, alpha-L-fucosidase (AFU) and transforming growth factor-beta 1 (TGF-β1) in the diagnosis and follow up of Egyptian patients with hepatocellular carcinoma in an attempt to find a tumor marker with a reasonable sensitivity and specificity for diagnosis of HCC and monitoring patients after therapy. The study was conducted on 4 selected groups of patients and a control group. Group I included 10 patients with liver cirrhosis. Group II consisted of 10 patients with benign hepatic focal lesions. Group III included 10 HCC patients without distant metastasis and group IV included 10 HCC patients presenting with metastasis. Ten apparently healthy age and sex matched subjects were also included and served as control group. AFP, sialic acid, alpha-L-fucosidase (AFU), VEGF, PIVKA-II and TGF-β1 were determined in the blood of five studied groups. The sensitivity and specificity of the tumor markers were calculated and compared. Significant differences in the median blood levels of AFP, PIVKA-II, VEGF, sialic acid, TGF-β1 and alpha-Lfucosidase activity (AFU) were found on comparing the HCC groups (with and without metastasis) with the other groups. The median blood levels of PIVKA-II, αfetoprotein level, sialic acid and AFU activity were lower in the HCC group without metastasis compared to that with metastasis (p<0.001). On the other hand, the median serum VEGF level was higher in the HCC group without metastasis compared to that of the HCC group with distant metastasis(p<0.001). Serum TGF-β1 level did not vary significantly between both groups (with and without metastasis) (p>0.05). There were significant lower median blood levels of all parameters in HCC patients without metastasis after ablation therapy compared to pretreatment levels. Combined determination of serological markers could be used as a highly valuable tool for screening and diagnosis of HCC as combination of these markers improved their sensitivity and specificity. They could also be used as prognostic markers decreasing the need for more invasive procedures.

show abstract

Comparison of serum and bronchoalveolar lavage fluid sialic acid levels between malignant and benign lung diseases

Abstract: Background: It is known that tissue and serum sialic acid levels may be altered by malignant transformation. In this study, sialic acid levels were determined in bronchoalveolar lavage fluid (BAL) and serum in two groups of patients with lung cancer and non-malignant diseases of the lung.

Cited by 4 publications

References 11 publications

The level of sialic acids and imidazole compounds in the saliva of patients with lung cancer of different histological types

The level of sialic acids and imidazole compounds in the saliva of patients with lung cancer of different histological types

Sialic Acid Value in Pleural Effusion as a Diagnostic Marker of Malignancy

Diagnostic and Predictive Value of Some Tumor Markers in the Diagnosis and Follow Up of Patients with Hepatocellular Carcinoma

Contact Info

Product

Resources

About